Author: PharmaSignal News Desk

Glenmark Hengrui licensing deal secures $1 billion, granting exclusive rights and impacting the pharmaceutical market.

Successful drug launches need realistic forecasts and market preparation, says Jason O’Neill, highlighting common pitfalls in new product launches.

GSK CEO transition sees Emma Walmsley stepping down, with Luke Miels set to take over on 1 January 2026.

Cipla Q1 earnings beat forecast, leading to a 5% share increase on 10 September 2025.

FDA warning letters target misleading advertising by Novo Nordisk, Eli Lilly, and Hims, urging improved transparency and compliance.

Pfizer Metsera acquisition enhances its obesity drug portfolio with promising GLP-1 and amylin candidates for $4.9 billion.

FDA approves Forzinity for Barth syndrome, affecting 150 people in the U.S., after months of regulatory uncertainty.

Successful drug launches face challenges like market timing and product advantage. Learn how to overcome these with insights from Jason O’Neill.

FDA warning letters target misleading drug ads, raising concerns about agency’s staffing for enforcement.

GSK $30B investment aims to expand US manufacturing, countering global pricing challenges.